Sign up to The Irish Times Archive (1859 - 2008)My Account »

Johnson & Johnson is to acquire the rights to Elan’s Alzheimer therapy programme in a $1.5 billion investment announced today.

In a statement, the companies said they had reached a “definitive agreement” whereby Johnson & Johnson will acquire “substantially all of the assets and rights of Elan related to its Alzheimer’s Immunotherapy Program (AIP Program), through a newly formed company”.